Market Cap 16.58B
Revenue (ttm) 4.10B
Net Income (ttm) 565.70M
EPS (ttm) N/A
PE Ratio 17.47
Forward PE 16.59
Profit Margin 13.80%
Debt to Equity Ratio 0.50
Volume 1,770,263
Avg Vol 3,208,070
Day's Range N/A - N/A
Shares Out 222.42M
Stochastic %K 88%
Beta 0.65
Analysts Sell
Price Target $76.86

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 508 263 2900
Address:
250 Campus Drive, Marlborough, United States
JazzyJ03
JazzyJ03 Nov. 14 at 4:18 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:38 AM
$HOLX is currently trading at $74.26, showing a strong upward momentum as indicated by an RSI of 59.06, which suggests it is not yet overbought. The price is above both the 30-day moving average (MA30) of 71.69 and the 50-day moving average (MA50) of 69.62, reinforcing a bullish trend. The recent high of $74.71 indicates potential resistance, while the 60-day low of $63.19 provides a solid support level. For a trade plan, consider entering at $74.00, just below the last close to confirm bullish momentum. Set a stop loss at $73.50 to manage risk. Target 1 can be set at $75.00, just above the recent high, while Target 2 can be set at $76.00, allowing for further upside potential. This plan leverages current momentum while maintaining a favorable risk-reward ratio. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 2:29 PM
$HOLX expands its digital diagnostics footprint in the EU! 🚀 Genius Digital Diagnostics System now has expanded CE marking for cell and tissue imaging, boosting lab efficiency and diagnostic accuracy. This innovation could redefine cancer diagnosis across Europe. Discover the impact on HOLX's growth and valuation here 👉 https://www.zacks.com/stock/news/2790414/hologic-expands-european-reach-of-genius-digital-diagnostics-system?cid=sm-stocktwits-2-2790414-body-20853&ADID=SYND_STOCKTWITS_TWEET_2_2790414_BODY_20853
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 1:23 PM
$HOLX expanding in Europe — quiet move, big implications. The company’s Genius Digital Diagnostics System is gaining broader European reach, signaling growth momentum in its diagnostics segment and stronger international positioning. See why this expansion could matter for Hologic’s next leg up 👉 https://www.zacks.com/stock/news/2790414/hologic-expands-european-reach-of-genius-digital-diagnostics-system?cid=sm-stocktwits-2-2790414-teaser-20820&ADID=SYND_STOCKTWITS_TWEET_2_2790414_TEASER_20820
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:45 AM
$HOLX is currently trading at $74.61, showing a strong bullish momentum with an RSI of 76.06, indicating overbought conditions. The price is near the 60-day high of $74.71, suggesting potential resistance at this level. The 30-day moving average (MA30) at $71.22 and the 50-day moving average (MA50) at $69.29 indicate a strong upward trend, providing support levels if a pullback occurs. Given the current market context, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $74.00, slightly below the last close, to capture potential upward movement. A stop loss can be placed at $73.00 to manage risk. For targets, consider $75.50 as the first target, just above the 60-day high, and $76.50 as a second target, allowing for further upside potential. https://privateprofiteers.com
0 · Reply
mwinc24
mwinc24 Nov. 12 at 6:38 PM
$HOLX lets crack $75
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:21 AM
$HOLX is currently trading at $74.61, showing a strong bullish momentum with an RSI of 76.06, indicating overbought conditions. The price is near the 60-day high of $74.71, suggesting potential resistance at this level. The 30-day moving average (MA30) at $71.22 and the 50-day moving average (MA50) at $69.29 indicate a strong upward trend, providing support levels if a pullback occurs. Given the current market context, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $74.00, slightly below the last close, to capture potential upward movement. A stop loss can be placed at $73.00 to manage risk. For targets, consider $75.50 as the first target, just above the 60-day high, and $76.50 as a second target, allowing for further upside potential. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:42 PM
Morgan Stanley updates rating for Hologic ( $HOLX ) to Equal-Weight, target set at 69 → 76.
0 · Reply
ZacksResearch
ZacksResearch Nov. 7 at 1:40 PM
$HOLX shares up 2.9% YTD — but is the stock undervalued? 🤔 Hologic's Breast Health division shows promising growth, boosting its revenues by 4.8% with strong U.S. sales and strategic changes. Plus, the proposed buyout by Blackstone and TPG places greater strategic focus on the division. See how Hologic's fiscal 2026 and 2027 earnings are projected 👉 https://www.zacks.com/stock/news/2787560/hologics-breast-health-rebounds-takes-spotlight-in-buyout-deal?cid=sm-stocktwits-2-2787560-body-20015&ADID=SYND_STOCKTWITS_TWEET_2_2787560_BODY_20015
0 · Reply
ZacksResearch
ZacksResearch Nov. 7 at 12:39 PM
$HOLX back in focus — Breast Health segment making a comeback 💪 The rebound in Hologic’s Breast Health unit is driving renewed investor attention, especially as the spotlight shifts to its latest buyout deal. See what’s fueling the momentum here 👉 https://www.zacks.com/stock/news/2787560/hologics-breast-health-rebounds-takes-spotlight-in-buyout-deal?cid=sm-stocktwits-2-2787560-teaser-19981&ADID=SYND_STOCKTWITS_TWEET_2_2787560_TEASER_19981
0 · Reply
Latest News on HOLX
Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

Oct 21, 2025, 9:18 AM EDT - 24 days ago

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

BX TPG


Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 7:12 PM EDT - 3 months ago

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript


Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 3:48 PM EDT - 6 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?


Hologic: Soft Performance, But Cheap Enough

May 6, 2025, 5:39 PM EDT - 6 months ago

Hologic: Soft Performance, But Cheap Enough


Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 8:24 PM EDT - 7 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript


Wayde McMillan Elected to Hologic Board of Directors

Apr 4, 2025, 4:15 PM EDT - 7 months ago

Wayde McMillan Elected to Hologic Board of Directors


Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 20, 2025, 3:00 AM EST - 9 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software


Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 18, 2025, 8:08 AM EST - 9 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay


Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 10:06 PM EST - 10 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript


Hologic: Reasonably, But Not Compellingly Valued

Jan 17, 2025, 1:28 PM EST - 10 months ago

Hologic: Reasonably, But Not Compellingly Valued


Hologic Completes Acquisition of Gynesonics, Inc.

Jan 6, 2025, 8:05 AM EST - 11 months ago

Hologic Completes Acquisition of Gynesonics, Inc.


JazzyJ03
JazzyJ03 Nov. 14 at 4:18 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:38 AM
$HOLX is currently trading at $74.26, showing a strong upward momentum as indicated by an RSI of 59.06, which suggests it is not yet overbought. The price is above both the 30-day moving average (MA30) of 71.69 and the 50-day moving average (MA50) of 69.62, reinforcing a bullish trend. The recent high of $74.71 indicates potential resistance, while the 60-day low of $63.19 provides a solid support level. For a trade plan, consider entering at $74.00, just below the last close to confirm bullish momentum. Set a stop loss at $73.50 to manage risk. Target 1 can be set at $75.00, just above the recent high, while Target 2 can be set at $76.00, allowing for further upside potential. This plan leverages current momentum while maintaining a favorable risk-reward ratio. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 2:29 PM
$HOLX expands its digital diagnostics footprint in the EU! 🚀 Genius Digital Diagnostics System now has expanded CE marking for cell and tissue imaging, boosting lab efficiency and diagnostic accuracy. This innovation could redefine cancer diagnosis across Europe. Discover the impact on HOLX's growth and valuation here 👉 https://www.zacks.com/stock/news/2790414/hologic-expands-european-reach-of-genius-digital-diagnostics-system?cid=sm-stocktwits-2-2790414-body-20853&ADID=SYND_STOCKTWITS_TWEET_2_2790414_BODY_20853
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 1:23 PM
$HOLX expanding in Europe — quiet move, big implications. The company’s Genius Digital Diagnostics System is gaining broader European reach, signaling growth momentum in its diagnostics segment and stronger international positioning. See why this expansion could matter for Hologic’s next leg up 👉 https://www.zacks.com/stock/news/2790414/hologic-expands-european-reach-of-genius-digital-diagnostics-system?cid=sm-stocktwits-2-2790414-teaser-20820&ADID=SYND_STOCKTWITS_TWEET_2_2790414_TEASER_20820
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:45 AM
$HOLX is currently trading at $74.61, showing a strong bullish momentum with an RSI of 76.06, indicating overbought conditions. The price is near the 60-day high of $74.71, suggesting potential resistance at this level. The 30-day moving average (MA30) at $71.22 and the 50-day moving average (MA50) at $69.29 indicate a strong upward trend, providing support levels if a pullback occurs. Given the current market context, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $74.00, slightly below the last close, to capture potential upward movement. A stop loss can be placed at $73.00 to manage risk. For targets, consider $75.50 as the first target, just above the 60-day high, and $76.50 as a second target, allowing for further upside potential. https://privateprofiteers.com
0 · Reply
mwinc24
mwinc24 Nov. 12 at 6:38 PM
$HOLX lets crack $75
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:21 AM
$HOLX is currently trading at $74.61, showing a strong bullish momentum with an RSI of 76.06, indicating overbought conditions. The price is near the 60-day high of $74.71, suggesting potential resistance at this level. The 30-day moving average (MA30) at $71.22 and the 50-day moving average (MA50) at $69.29 indicate a strong upward trend, providing support levels if a pullback occurs. Given the current market context, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $74.00, slightly below the last close, to capture potential upward movement. A stop loss can be placed at $73.00 to manage risk. For targets, consider $75.50 as the first target, just above the 60-day high, and $76.50 as a second target, allowing for further upside potential. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:42 PM
Morgan Stanley updates rating for Hologic ( $HOLX ) to Equal-Weight, target set at 69 → 76.
0 · Reply
ZacksResearch
ZacksResearch Nov. 7 at 1:40 PM
$HOLX shares up 2.9% YTD — but is the stock undervalued? 🤔 Hologic's Breast Health division shows promising growth, boosting its revenues by 4.8% with strong U.S. sales and strategic changes. Plus, the proposed buyout by Blackstone and TPG places greater strategic focus on the division. See how Hologic's fiscal 2026 and 2027 earnings are projected 👉 https://www.zacks.com/stock/news/2787560/hologics-breast-health-rebounds-takes-spotlight-in-buyout-deal?cid=sm-stocktwits-2-2787560-body-20015&ADID=SYND_STOCKTWITS_TWEET_2_2787560_BODY_20015
0 · Reply
ZacksResearch
ZacksResearch Nov. 7 at 12:39 PM
$HOLX back in focus — Breast Health segment making a comeback 💪 The rebound in Hologic’s Breast Health unit is driving renewed investor attention, especially as the spotlight shifts to its latest buyout deal. See what’s fueling the momentum here 👉 https://www.zacks.com/stock/news/2787560/hologics-breast-health-rebounds-takes-spotlight-in-buyout-deal?cid=sm-stocktwits-2-2787560-teaser-19981&ADID=SYND_STOCKTWITS_TWEET_2_2787560_TEASER_19981
0 · Reply
CousinOfPepe
CousinOfPepe Nov. 5 at 10:13 PM
$HOLX peculiar buys today and after hours. 🤔
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 5 at 1:02 AM
$HOLX Share Price: $74.13 Contract Selected: Jun 18, 2026 $75 Calls Buy Zone: $0.98 – $1.21 Target Zone: $1.75 – $2.14 Potential Upside: 69% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JazzyJ03
JazzyJ03 Nov. 4 at 8:28 PM
$HOLX Doesn’t look to bad!
1 · Reply
ZacksResearch
ZacksResearch Nov. 4 at 2:13 PM
$HOLX surges post-earnings — is the rally sustainable? 🚀 Hologic beat Q4 estimates with adjusted EPS up 11.9% YoY and revenues rising 6.2%, but the spotlight is on its acquisition deal with Blackstone and TPG for $76 per share in cash, plus a CVR of up to $3. The transaction is expected to close in early 2026. See what this means for investors 👉 https://www.zacks.com/stock/news/2784288/holx-stock-up-on-q4-earnings-revenue-beat-operating-margin-expands?cid=sm-stocktwits-2-2784288-body-19265&ADID=SYND_STOCKTWITS_TWEET_2_2784288_BODY_19265
0 · Reply
ZacksResearch
ZacksResearch Nov. 4 at 1:12 PM
$HOLX just delivered a clean beat 👏 Q4 earnings and revenues both topped expectations, and operating margin expanded — a strong combo that signals real operational strength. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2784288/holx-stock-up-on-q4-earnings-revenue-beat-operating-margin-expands?cid=sm-stocktwits-2-2784288-teaser-19248&ADID=SYND_STOCKTWITS_TWEET_2_2784288_TEASER_19248
0 · Reply
jamie9_greene
jamie9_greene Nov. 3 at 8:13 PM
$HOLX NXXT bid dominance shows in prints green streaks streaming across T&S buyers not waiting for perfect price next resistance 2.10 break unleashes speed 🔥
0 · Reply
DonCorleone77
DonCorleone77 Nov. 3 at 7:31 PM
$PLTR $CLX $HOLX $LSCC $QRVO Some notable companies reporting after the market close, with earnings consensus estimataes: -- Palantir (PLTR), consensus 17c -- Clorox (CLX), consensus 78c -- Hologic (HOLX), consensus $1.10 -- Lattice (LSCC), consensus 28c -- Qorvo (QRVO), consensus $2.11
0 · Reply
mwinc24
mwinc24 Nov. 3 at 7:20 PM
$HOLX no volume.. I just want a 5% increase before Nov. 21st. Nothing crazy lol
1 · Reply
mwinc24
mwinc24 Nov. 3 at 12:48 AM
$SPY $HOLX after hrs earnings play
0 · Reply
ChessGM
ChessGM Nov. 1 at 11:56 PM
$HOLX "Heads up alert! Only two days until Upcoming earnings on Monday, 11/3/2025 for $HOLX Bullish (7.5) --- The latest developments surrounding Hologic, Inc. (NASDAQ: HOLX) indicate a robust outlook for the company, particularly in light of its recent acquisition agreement with Blackstone and TPG, valued at up to $18.3 billion. This strategic move is anticipated to enhance Hologic's market position, especially as it focuses on women's health technologies. Financially, Hologic has demonstrated solid performance metrics, with a P/E ratio of approximately 20, which is competitive within the medical technology sector. The company's earnings per share (EPS) growth has been notable, with projections indicating a high-single-digit increase for the upcoming quarter, reflecting a recovery trajectory following a challenging year. Revenue forecasts suggest an annual growth rate of around 5%, driven by strong demand for its diagnostic and surgical products, particularly in the breast health segment. Comparatively, Hologic's performance is on par with industry peers such as Abbott Laboratories, which has also shown resilience and growth, albeit with more diversified operations. In terms of operational metrics, Hologic's recent FDA approvals for its Panther Fusion GI assays are expected to bolster its diagnostics portfolio, enhancing its revenue-generating capabilities. The company has successfully navigated market challenges, showing a 20% increase in net income alongside a 5% rise in revenue, which reflects its operational efficiency and strategic focus on innovation. Despite underperforming the S&P 500 over the past year, the recent acquisition news and positive earnings outlook have reinvigorated investor interest, leading to a share price recovery of approximately 9% over the last 90 days. --- Regarding upcoming earnings reports, Hologic is set to announce its fourth-quarter fiscal results on November 3, 2025. Analysts are cautiously optimistic, with consensus estimates indicating a strong performance driven by increased revenues and improved margins. Historical performance suggests that Hologic has often exceeded earnings expectations, which could positively influence market sentiment post-announcement. The anticipated earnings report is expected to highlight the impact of recent strategic initiatives, including new product launches and enhanced operational efficiencies. The healthcare sector, to which Hologic belongs, has shown resilience, with health care stocks generally advancing in recent trading sessions. The NYSE Health Care Index has seen a modest increase of approximately 0.1%, reflecting investor confidence in the sector's growth potential amidst broader market fluctuations. This context underscores Hologic's positioning within a favorable sector environment, potentially amplifying the positive impact of its forthcoming earnings report and strategic initiatives. - Funds were net buyers of $HOLX during the previous reporting quarter. - Funds with large holdings in $HOLX include: - Adage Capital P, MV: $48MM. New position. Fund Rank: 89% www.adagecapital.com - Alyeska Investments, MV: $27MM. New position. Fund Rank: 79% - Last 10 days performance: 0% - Last 30 days performance: 9% - Last 90 days performance: 10% Some of the latest news articles: - Title: HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment? Publication Date: 10/30/2025 1:06:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/holx-vs-abt-medical-technology-130600952.html?.tsrc=rss - Title: Gear Up for Hologic (HOLX) Q4 Earnings: Wall Street Estimates for Key Metrics Publication Date: 10/29/2025 1:15:08 PM, Source: yahoo URL: https://finance.yahoo.com/news/gear-hologic-holx-q4-earnings-131508225.html?.tsrc=rss - Title: PainTEQ Scales Leadership: Med-Tech Catalyst Robert Kline Joins Board to Drive New Standard in Interventional Spine Care Publication Date: 10/28/2025 9:08:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/painteq-scales-leadership-med-tech-090800310.html?.tsrc=rss - Title: Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Publication Date: 10/27/2025 2:00:16 PM, Source: yahoo URL: https://finance.yahoo.com/news/hologic-holx-earnings-expected-grow-140016738.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
Tat2doc
Tat2doc Oct. 31 at 1:55 PM
$HOLX how is a guaranteed 7% gain in 6 months getting a bearish sentiment on Stocktwits? 😂😂😂 Better yet, if Blackstone deal doesn’t go through, this stock has ~20% upside. Wish I owned a shit load of this, but it’s a good little piece of the puzzle.
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 1:50 PM
$HOLX to go private — but is it worth the wait? 🤔 🔍 Deal valued at $18.3B, offering $76/share + CVR of up to $3/share 📈 Shares closed at $73.98, implying an upside potential of 2.7% to the $76 offer 📊 Q4 earnings could reveal more about Breast Health growth See if Hologic's upside is worth the hold here 👉 https://www.zacks.com/stock/news/2781244/holx-vs-abt-which-medical-technology-stock-is-the-better-investment?cid=sm-stocktwits-2-2781244-body-18469&ADID=SYND_STOCKTWITS_TWEET_2_2781244_BODY_18469
0 · Reply